Literature DB >> 8808440

Fulminant hepatitis caused by hepatitis C virus during treatment for multiple sclerosis.

M Funaoka1, K Kato, M Komatsu, T Ono, T Hoshino, J Kato, T Kuramitsu, T Ishii, I Toyoshima, O Masamune.   

Abstract

A 55-year-old woman was treated at our hospital for multiple sclerosis. Therapy consisted of glucocorticosteroids and cyclosporin. In the 7th week after these drugs were discontinued the patient developed acute liver failure due to fulminant hepatitis (FH) and died. Post-mortem examination showed massive liver necrosis. Serologic examination was negative for hepatitis B virus-related markers. Antihepatitis C virus (anti-HCV) antibody and serum HCV RNA were negative on admission, but HCV RNA appeared concurrently with the onset of FH. Although HCV infection rarely causes FH, it was considered to be the cause of FH in this patient, since there were no other causes of acute liver injury. We suspect that underlying immunologic abnormalities in conjunction with HCV infection may have precipitated the FH.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8808440     DOI: 10.1007/bf01211198

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  8 in total

1.  Hepatitis C virus not found in fulminant non-A, non-B hepatitis.

Authors:  T L Wright; H Hsu; E Donegan; S Feinstone; H Greenberg; A Read; N L Ascher; J P Roberts; J R Lake
Journal:  Ann Intern Med       Date:  1991-07-15       Impact factor: 25.391

2.  Hepatitis C virus in fulminant hepatic failure.

Authors:  M Yanagi; S Kaneko; M Unoura; S Murakami; K Kobayashi; J Sugihara; H Ohnishi; Y Muto
Journal:  N Engl J Med       Date:  1991-06-27       Impact factor: 91.245

3.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

4.  Contribution of hepatitis C virus to non-A, non-B fulminant hepatitis in Japan.

Authors:  M Yoshiba; K Dehara; K Inoue; H Okamoto; M Mayumi
Journal:  Hepatology       Date:  1994-04       Impact factor: 17.425

5.  Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis.

Authors:  C Féray; M Gigou; D Samuel; G Reyes; J Bernuau; M Reynes; H Bismuth; C Bréchot
Journal:  Gastroenterology       Date:  1993-02       Impact factor: 22.682

6.  Fulminant or subfulminant non-A, non-B viral hepatitis: the role of hepatitis C and E viruses.

Authors:  T J Liang; L Jeffers; R K Reddy; M O Silva; H Cheinquer; A Findor; M De Medina; P O Yarbough; G R Reyes; E R Schiff
Journal:  Gastroenterology       Date:  1993-02       Impact factor: 22.682

7.  Hepatitis B virus and apparent fulminant non-A, non-B hepatitis.

Authors:  T L Wright; D Mamish; C Combs; M Kim; E Donegan; L Ferrell; J Lake; J Roberts; N L Ascher
Journal:  Lancet       Date:  1992-04-18       Impact factor: 79.321

8.  Fulminant hepatitis following bone marrow transplantation in hepatitis B virus carrier siblings.

Authors:  F Omata; F Ueno; Y Kushibiki; H Takahashi
Journal:  J Gastroenterol       Date:  1994-10       Impact factor: 7.527

  8 in total
  1 in total

1.  Pericentral liver cell necrosis associated with the use of high-dose intravenous methylprednisolone.

Authors:  Hannah M Lee; Jeremy S Ditelberg; Marshall M Kaplan
Journal:  Dig Dis Sci       Date:  2007-04-04       Impact factor: 3.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.